Switch Outcomes From Biologics to JAK Inhibitors in Atopic Dermatitis

Panelists discuss how switching therapies is a critical step when patients experience incomplete response or intolerance to biologics like dupilumab. They explain that transitioning to oral Janus kinase (JAK) inhibitors, such as upadacitinib or abrocitinib, can lead to rapid and significant improvements in itch relief and skin clearance, often within weeks of the switch. These outcomes highlight the versatility of JAK inhibitors in achieving disease control where prior treatments plateaued.

Panelists share that patient experiences confirm the clinical data: Many who switch therapies regain confidence in their treatment plan as symptoms stabilize and quality of life improves. The rapid onset of action, oral dosing convenience, and broader immune modulation contribute to both physician and patient satisfaction.

They emphasize that treatment sequencing should be individualized—considering disease severity, prior response, risk profile, and patient preference—to optimize outcomes. The ability to successfully transition patients reinforces JAK inhibitors as a vital component of the evolving therapeutic algorithm for atopic dermatitis.